Dyne Therapeutics, Inc.

NASDAQ:DYN

Biotechnology

Healthcare
$15.87 +1.97%

+$0.38 today

Market cap
$2.97B
Beta
1.08
P/E (TTM)
-7.2
EPS (TTM)
-$2.74
52W Low $8.06High $25.00

Volume 2.93M

Average 1.71M

DYN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Dyne Therapeutics, Inc.NASDAQ: DYN

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q2 FY2026 depreciation & amortization of $560K rose 11.3% year over year, behind the +13.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.8% from the prior quarter. Over 3 fiscal years it compounded at +6.8% a year.

Context

  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.3% toward the trailing-twelve-month pace of +13.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$560K+1.8% QoQ
Last fiscal yearDec 2025
$2.05M+22.5% YoY
LTMJun 2026
$2.15M+13.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.3%——
1 year+22.5%——
3-year CAGR+6.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
2.05M USD
Year-over-year change
+22.5%
4-year CAGR
+17.1%

Depreciation & Amortization vs competitors

How DYN compares with its peers on the latest reported figures

  • DYN's LTM Jun 2026 depreciation & amortization of $2.15M is the 9th largest of the 11 companies compared; the peer median is $5.68M.
  • Its year-over-year change of +13.8% is the 6th highest of 11, against a peer median of +12.4%.
  • Over three fiscal years its annual growth of +6.8% compares with a peer median of +3.3%.
DYN Competitors Peer median
Depreciation & Amortization for DYN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.25B +83349.3%+52.5%—
PTCTPTC Therapeutics, Inc.LTM Jun 2026$55.3M +97.1%-33.0%5.5%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$45.14M +15.9%+2.1%2.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$28.19M +36.7%+0.9%2.9%
WVEWave Life Sciences Ltd.LTM Mar 2026$8.15M -5.8%-4.3%11.4%
PEPGPepGen Inc.LTM Mar 2026$3.2M -5.6%+118.5%—
STOKStoke Therapeutics, Inc.LTM Mar 2026$2.28M +9.0%+4.6%7.1%
SLDBSolid Biosciences Inc.LTM Mar 2026$2.18M -186.0%——
DYNDyne Therapeutics, Inc.LTM Jun 2026$2.15M +13.8%+6.8%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$326K +176.0%——
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$284K -92.5%+29.3%4.9%
Peer median (excluding DYN) $5.68M+12.4%+3.3%5.2%

Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(149.29M)(168.1M)(235.94M)(317.42M)(446.21M)
Depreciation & Amortization1.09M1.68M1.67M1.67M2.05M
Deferred Income Tax2.59M0000
Stock-Based Compensation17.54M15.18M19.97M45.86M45.85M
Change in Working Capital9.26M(5.38M)26.31M(19.49M)(3.4M)
Accounts Receivables00000
Inventory00000
Accounts Payables13.7M(1.24M)22.97M(8.96M)8.25M
Other Working Capital(4.45M)(4.14M)3.34M(10.54M)(11.65M)
Other Non-Cash Items(746K)2.97M(173K)(3M)(1.49M)
Operating Cash Flow(119.56M)(153.65M)(188.16M)(292.37M)(403.21M)
Capital Expenditures(3.62M)(3.07M)(729K)(2.38M)(1.92M)
Acquisitions (Net)8K34K000
Purchases of Investments(236.72M)(121.18M)(44.26M)(317.44M)(180.53M)
Sales of Investments102.45M211.45M128.3M115.71M172.46M
Other Investing Activities(8K)(34K)035K(18.76M)
Investing Cash Flow(137.89M)87.2M83.31M(204.08M)(28.75M)
Debt Repayment0000147.7M
Common Stock Issued157.24M36.86M52.37M773.05M742.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities584K529K1.95M36.84M0
Financing Cash Flow157.82M37.39M54.32M809.9M890.31M
Effect of Forex Changes00000
Net Change in Cash(99.63M)(29.05M)(50.53M)313.45M458.35M
Free Cash Flow(123.18M)(156.71M)(188.89M)(294.75M)(405.13M)

Dyne Therapeutics, Inc.

NASDAQ:DYN

Intrinsic Alpha fair value

Locked

Current Price

$15.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.